Propanc Sets Q1 2027 Start for First-in-Human PRP Trial in Advanced Solid Tumors
PPCB is trading near its 52-week low of $0.518 (2.4% above the low) on light trading volume (0.2× avg).
Summary
Propanc Biopharma announced plans to begin a Phase 1b first-in-human trial of its lead candidate PRP in Q1 2027, targeting up to 50 patients with advanced solid tumors including pancreatic, ovarian, and refractory prostate cancers. The company has secured key operational partnerships—an MOU with CRO Avance Clinical, a CDMO for GMP manufacturing, and a PK assay agreement with FyoniBio—to support the study. New preclinical data showed >90% tumor growth inhibition and >2.5-fold survival extension in pancreatic cancer models, building on prior results. Financially, the company raised $7.5 million in FY2026 and reported $832K in cash at year-end, with a further $2 million received post-period. This follows the 10-K filed September 25, which disclosed a going concern warning and $18.9M net loss; the trial timeline and partnerships provide a concrete path forward but execution risk remains high given the cash position. The company also started a $5 million buyback.
At the time of this announcement, PPCB was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.52 to $52.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.